Article

Acquisition of anoikis resistance through CD147 upregulation: A new mechanism underlying metastasis of hepatocellular carcinoma cells.

State Key Laboratory of Bioreactor Engineering, East China University of Science and Technology, Shanghai 200237.
Oncology letters (Impact Factor: 0.24). 06/2012; 3(6):1249-1254. DOI: 10.3892/ol.2012.658
Source: PubMed

ABSTRACT Acquisition of anoikis resistance is a prerequisite for the metastasis of hepatocellular carcinoma (HCC) cells. Activation of growth factor signaling pathways and rearrangement of the cytoskeleton have been reported as vital steps in this process. However, key molecules involved in anoikis resistance remain to be determined. The aim of this study was to investigate the effect of CD147 on HCC cells resistant to anoikis. The human SMMC-7221 human HCC cell line was used. Immunofluorescence was used to investigate the expression levels of CD147. Anoikis-induced cell death was assessed using trypan blue exclusion. In the present study, the results showed that SMMC-7721 HCC cells exhibited significant morphological changes when suspended in culture medium supplemented with 1% methocel and a subpopulation of cells resistant to anoikis was acquired with higher viability and invasion ability. CD147 was identified to be significantly increased in cells resistant to anoikis, when compared to the parental cells. CD147 knockdown by siRNA notably induced cell anoikis, partially through the inactivation of PI3K/Akt pathway. All of these evidence provide a novel CD147-related mechanism underlying the metastasis of HCC cells.

0 Bookmarks
 · 
167 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The aim of the present study was to examine the safety and efficacy of a peripheral intravenous bolus of Licartin for the treatment of advanced hepatocellular carcinoma (HCC), and to explore the clinical value of this treatment. Clinical data from Tianjin Medical University Cancer Institute and Hospital (Tianjin, China) were analyzed. Thirty-three patients (38 cases) with advanced HCC received an intravenous bolus of Licartin. The patients underwent routine blood examinations and liver, kidney and thyroid function tests 1 week prior to treatment and 1 and 3 months after treatment, and a long-term follow-up was performed. These data were collected before and after treatment was statistically analyzed and compared with that of previous studies regarding the safety of Licartin combined with transcatheter arterial chemoembolization for the treatment of HCC. During treatment, adverse reactions, including non-infectious fever, pain in the liver area, nausea and vomiting, occurred in a minority of patients. The adverse reactions were endured in the majority of cases and the symptoms were spontaneously relieved. Following treatment, 15 patients (39.47% of cases) demonstrated drug-related adverse reactions, including decreased white blood cell counts, platelet counts, hemoglobin levels and neutrophil counts, and increased levels of alanine aminotransferase, aspartate aminotransferase, serum direct bilirubin, creatinine and blood urea nitrogen, from high to low incidence. Electrocardiograms indicated no significant differences in thyroid function between patients before and after treatment, and showed stable vital signs. This study demonstrated that peripheral intravenous bolus administration of Licartin for radioimmunotherapy is safe and effective, is tolerated by the patient and may potentially become a routine treatment for HCC.
    Experimental and therapeutic medicine 12/2013; 6(6):1417-1422. · 0.34 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: STAT3 plays a critical role in initiation and progression of pancreatic cancer. However, therapeutically targeting STAT3 is failure in clinic. We previously identified HAb18G/CD147 as an effective target for cancer treatment. In this study, we aimed to investigate potential role of HAb18G/CD147 in STAT3-involved pancreatic tumorigenesis in vitro and in vivo. The expression of HAb18G/CD147, pSTAT3 and CD44s were determined in tissue microarrays. The tumorigenic function and molecular signaling mechanism of HAb18G/CD147 was assessed by in vitro cellular and clonogenic growth, reporter assay, immunoblot, immunofluorescence staining, immunoprecipitation, and in vivo tumor formation using loss or gain-of-function strategies. ResultsHighly expressed HAb18G/CD147 promoted cellular and clonogenic growth in vitro and tumorigenicity in vivo. CyPA, a ligand of CD147, stimulated STAT3 phosphorylation and its downstream genes cyclin D1/survivin through HAb18G/CD147 dependent mechanisms. HAb18G/CD147 was associated and co-localized with cancer stem cell marker CD44s in lipid rafts. The inhibitors of STAT3 and survivin, as well as CD44s neutralizing antibodies suppressed the HAb18G/CD147-induced cell growth. High HAb18G/CD147 expression in pancreatic cancer was significantly correlated with the poor tumor differentiation, and the high co-expression of HAb18G/CD147-CD44s-STAT3 associated with poor survival of patients with pancreatic cancer. Conclusions We identified HAb18G/CD147 as a novel upstream activator of STAT3 via interacts with CD44s and plays a critical role in the development of pancreatic cancer. The data suggest HAb18G/CD147 could be a promising therapeutic target for highly aggressive pancreatic cancer and a surrogate marker in the STAT3-targeted molecular therapies.
    Clinical Cancer Research 10/2013; · 7.84 Impact Factor

Full-text (2 Sources)

View
6 Downloads
Available from
May 30, 2014